GGI
ONCT

Godsey & Gibb Inc’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Godsey & Gibb Inc’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed -$15 – 385
2023
Q1 		$15 Hold
1
– – ﹤0.01% 334
2022
Q4 		$18 Hold
1
– – ﹤0.01% 299
2022
Q3 		$0 Buy
+1
New +$21 ﹤0.01% 170

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Godsey & Gibb Inc's ONCT Position: Q2 2023 in Review

Godsey & Gibb Inc sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2023, closing a stake of 1 share — an estimated $15 sold.

Godsey & Gibb Inc first reported a position in ONCT in Q3 2022 and held it in 3 quarters. The position peaked at $18 in Q4 2022. 52 funds tracked by Wall St. Rank hold ONCT as of Q2 2023.

  • Godsey & Gibb Inc reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Godsey & Gibb Inc sold 1 Oncternal Therapeutics, Inc. Common Stock share in Q2 2023, an estimated $15.
  • Godsey & Gibb Inc first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Godsey & Gibb Inc's Oncternal Therapeutics, Inc. Common Stock position peaked at $18 in Q4 2022.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Godsey & Gibb Inc's 13F filing for Q2 2023, filed 25 Jul 2023.